Abstract
Background There are limited tools available to predict the long-term prognosis of persons with coronary chronic total occlusions (CTO).
Objectives We evaluated performance of a blood biomarker panel to predict cardiovascular (CV) events in patients with CTO.
Methods From 1251 patients in the CASABLANCA study, 241 participants with a CTO were followed for an average of 4 years for occurrence of major adverse CV events (MACE, CV death, non-fatal myocardial infarction or stroke) and CV death/heart failure (HF) hospitalization. Results of a biomarker panel (kidney injury molecule-1, N-terminal pro-B-type natriuretic peptide, osteopontin, and tissue inhibitor of metalloproteinase-1) from baseline samples were expressed as low-, moderate-, and high-risk.
Results By 4 years, a total of 67 (27.8%) MACE events and 56 (23.2%) CV death/HF hospitalization events occurred. The C-statistic of the panel for MACE through 4 years was 0.79. Considering patients in the low-risk group as a reference, the hazard ratio of MACE by 4 years was 6.65 (95% confidence interval [CI]: 2.98-14.8) and 12.4 (95% CI:5.17-29.6) for the moderate and high-risk groups (both P <0.001). The C-statistic for CVD/HF hospitalization by 4 years was 0.84. Compared to the low-risk score group, the moderate and high-risk groups had hazard ratios of 5.61 (95% CI: 2.33-13.5) and 15.6 (95% CI: 6.18, 39.2; both P value <0.001).
Conclusion A multiple biomarker panel assists in evaluating the risk of adverse outcomes in patients with coronary CTO. These results may have implications for patient care and could have a role for clinical trial enrichment.
Clinical Trial CASABLANCA, ClinicalTrials.gov Identifier: NCT00842868
Competing Interest Statement
Funding: Dr. Mohebi is supported by the Barry Fellowship. Dr. McCarthy is supported by the NHLBI T32 postdoctoral training grant (5T32HL094301-12). Dr. Januzzi is supported by the Hutter Family Professorship. Disclosures: Dr. McCarthy has received consulting income from Abbott Laboratories Dr. Jaffer: sponsored research: Canon, Siemens, Shockwave, Teleflex, Mercator, Boston Scientific, HeartFlow, Neovasc; consultant/speakers fees: Boston Scientific, Siemens, Magenta Medical, Philips, Biotronik, Mercator, Abiomed; Equity interest: Intravascular Imaging Inc, DurVena. Massachusetts General Hospital ? licensing arrangements: Terumo, Canon, Spectrawave, for which FAJ has right to receive royalties. Dr. Megarat and Ms. Rhyne are employees of Prevencio. Dr. Januzzi: is a Trustee of the American College of Cardiology; is a board member of Imbria Pharmaceuticals; has received grant support from Abbott Diagnostics, Applied Therapeutics, HeartFlow, Innolife and Novartis; has received consulting income from Abbott Diagnostics, AstraZeneca, Beckman Coulter, Jana Care, Janssen, Novartis, Prevencio, Quidel, Roche Diagnostics; and participates in clinical endpoint committees/data safety monitoring boards for AbbVie, Abbott, Bayer, Siemens, Pfizer and Takeda. The rest of the authors have no disclosure.
Clinical Trial
CASABLANCA, ClinicalTrials.gov Identifier: NCT00842868
Funding Statement
Funding: Dr. Mohebi is supported by the Barry Fellowship. Dr. McCarthy is supported by the NHLBI T32 postdoctoral training grant (5T32HL094301-12). Dr. Januzzi is supported by the Hutter Family Professorship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All study procedures were approved by the MassGeneral/Brigham HealthCare Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All the data for the manuscript is available
